Literature DB >> 1730922

Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease.

P Desreumaux1, A Janin, J F Colombel, L Prin, J Plumas, D Emilie, G Torpier, A Capron, M Capron.   

Abstract

Interleukin 5 (IL-5), the major factor involved in eosinophil differentiation, is produced by T cells or mast cells. In the present study, we found that eosinophils infiltrating the mucosa of four patients with active coeliac disease also express the IL-5 mRNA. No positive signal was obtained in normal duodenum tissues and in the cell infiltrate from patients submitted to gluten restriction. The identification of labeled mucosal cells as eosinophils relied on their typical morphology. Moreover, highly purified blood eosinophils from three out of four patients with eosinophilia were also strongly labeled with the IL-5 antisense but not with the corresponding sense probe. Together, these results suggest that eosinophils have the capacity to synthesize IL-5, which could contribute to paracrine interactions with T and B cells and, in autocrine fashion, locally participate, through binding to the IL-5 receptor, to eosinophil differentiation and activation. These data might have implications not only in the pathology of coeliac disease but also in other diseases associated with eosinophil infiltration.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730922      PMCID: PMC2119074          DOI: 10.1084/jem.175.1.293

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  Activated eosinophils in coeliac disease.

Authors:  J F Colombel; A Janin; G Torpier
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

2.  Heterogeneity of human peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia.

Authors:  L Prin; M Capron; A B Tonnel; O Bletry; A Capron
Journal:  Int Arch Allergy Appl Immunol       Date:  1983

3.  Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays.

Authors:  E Clutterbuck; J G Shields; J Gordon; S H Smith; A Boyd; R E Callard; H D Campbell; I G Young; C J Sanderson
Journal:  Eur J Immunol       Date:  1987-12       Impact factor: 5.532

4.  IL-2 mRNA expression in Tac-positive malignant lymphomas.

Authors:  M Peuchmaur; D Emilie; M C Crevon; P Solal-Celigny; M C Maillot; G Lemaigre; P Galanaud
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

5.  Human eosinophils express transforming growth factor alpha.

Authors:  D T Wong; P F Weller; S J Galli; A Elovic; T H Rand; G T Gallagher; T Chiang; M Y Chou; K Matossian; J McBride
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

6.  Recombinant human interleukin 5 is a selective activator of human eosinophil function.

Authors:  A F Lopez; C J Sanderson; J R Gamble; H D Campbell; I G Young; M A Vadas
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

7.  Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects.

Authors:  A B Kay; S Ying; V Varney; M Gaga; S R Durham; R Moqbel; A J Wardlaw; Q Hamid
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

8.  Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils.

Authors:  R Moqbel; Q Hamid; S Ying; J Barkans; A Hartnell; A Tsicopoulos; A J Wardlaw; A B Kay
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

9.  Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils.

Authors:  H Kita; T Ohnishi; Y Okubo; D Weiler; J S Abrams; G J Gleich
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

10.  Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor.

Authors:  Y Yamaguchi; Y Hayashi; Y Sugama; Y Miura; T Kasahara; S Kitamura; M Torisu; S Mita; A Tominaga; K Takatsu
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

View more
  45 in total

1.  Improvement of eosinophilic heart disease after steroid therapy: successful demonstration by endomyocardial biopsied specimens.

Authors:  S Hayashi; M Isobe; Y Okubo; J Suzuki; Y Yazaki; M Sekiguchi
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

Review 2.  The use of biologics for immune modulation in allergic disease.

Authors:  Willem van de Veen; Mübeccel Akdis
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

Review 3.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

Review 4.  Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.

Authors:  Matthew P Giannetti; Juan C Cardet
Journal:  Curr Allergy Asthma Rep       Date:  2016-11       Impact factor: 4.806

5.  Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity.

Authors:  B F DiCosmo; G P Geba; D Picarella; J A Elias; J A Rankin; B R Stripp; J A Whitsett; R A Flavell
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

6.  Mechanisms of eosinophilia in BALB/c-nu/+ and congenitally athymic BALB/c-nu/nu mice infected with Toxocara canis.

Authors:  Y Kusama; M Takamoto; T Kasahara; K Takatsu; H Nariuchi; K Sugane
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

7.  IL-5 in post-traumatic eosinophilic pleural effusion.

Authors:  L Schandené; B Namias; A Crusiaux; M Lybin; R Devos; T Velu; P Capel; R Bellens; M Goldman
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

8.  Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease.

Authors:  S Dubucquoi; A Janin; O Klein; P Desreumaux; P Quandalle; A Cortot; M Capron; J F Colombel
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

9.  Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice.

Authors:  C Zuany-Amorim; D Leduc; B B Vargaftig; M Pretolani
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

10.  Human eosinophils stimulate DNA synthesis and matrix production in dermal fibroblasts.

Authors:  T P Birkland; M D Cheavens; S H Pincus
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.